Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Arthritis Rheum ; 46(6): 1671-82, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12115200

ABSTRACT

OBJECTIVE: The receptor-binding B subunit of Escherichia coli heat-labile enterotoxin (EtxB) is a highly stable, nontoxic protein that is capable of modulating immune responses. This study was conducted to determine whether mucosal administration of EtxB can block collagen-induced arthritis (CIA) and to investigate the mechanisms involved. METHODS: Clinical arthritis in DBA/1 mice was monitored following mucosal administration of EtxB on 4 occasions. The dependence of disease prevention on receptor binding by EtxB and the associated alterations to the immune response to type II collagen (CII) were assessed. Adoptive transfer experiments and lymph node cell cocultures were used to investigate the underlying mechanisms. RESULTS: Both intranasal and intragastric delivery of EtxB were effective in preventing CIA; a 1-microg dose of EtxB was protective after intranasal administration. A non-receptor-binding mutant of EtxB failed to prevent disease. Intranasal EtxB lowered both the incidence and severity of arthritis when given either at the time of disease induction or 25 days later. EtxB markedly reduced levels of anti-CII IgG2a antibodies and interferon-gamma (IFNgamma) production while not affecting levels of IgG1, interleukin-4 (IL-4), or IL-10. Disease protection could be transferred by CD4+ T cells from treated mice, an effect that was abrogated upon depletion of the CD25+ population. In addition, CD4+CD25+ T cells from treated mice were able to suppress anti-CII IFNgamma production by CII-primed lymph node cells. CONCLUSION: Mucosal administration of EtxB can be used to prevent or treat CIA. Modulation of the anti-CII immune response by EtxB is associated with a reduction in Th1 cell reactivity without a concomitant shift toward Th2. Instead, EtxB mediates its effects through enhancing the activity of a population of CD4+ regulatory T cells.


Subject(s)
Adjuvants, Immunologic/pharmacology , Arthritis, Experimental/drug therapy , Arthritis, Experimental/prevention & control , Bacterial Toxins/pharmacology , CD4-Positive T-Lymphocytes/immunology , Enterotoxins/pharmacology , Escherichia coli Proteins , Adoptive Transfer , Animals , Arthritis, Experimental/immunology , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Autoimmune Diseases/prevention & control , CD4-Positive T-Lymphocytes/chemistry , CD4-Positive T-Lymphocytes/metabolism , Interferon-gamma/biosynthesis , Male , Mice , Mice, Inbred DBA , Receptors, Interleukin-2/analysis , Spleen/cytology , Spleen/immunology
2.
J Autoimmun ; 18(2): 149-57, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11908947

ABSTRACT

NZB mice spontaneously develop autoimmune haemolytic anaemia (AIHA) due to a T helper-dependent autoantibody response against the erythrocyte anion channel protein, Band 3. Here, we characterize the recognition of the Band 3 sequence 861-874, which carries the dominant, I-E(d)-restricted T cell epitope. The ability of N and C-terminal truncated versions of peptide 861-874 to elicit NZB splenic T-cell proliferation indicated that the core epitope spans residues 862-870. Next, a set of alanine substitution analogues was tested to determine which residues functioned either as MHC anchor or TCR contact residues. A combination of proliferation and MHC:peptide binding assays identified residues 862(L), 864(V), 865(L), and 869(K) as I-E(d) anchor residues, and 868(V) as the only TCR contact residue. The ability of the wild-type sequence 861-874 to compete with a high affinity reference peptide for binding to I-E(d) indicates that the escape of pathogenic NZB T cells from purging of the autoreactive repertoire cannot be attributed to ineffective presentation of peptide 861-874 by its restricting element. It will now be possible to design altered peptide ligands of Band 3 861-874, in order to further dissect the mechanisms responsible for the maintenance and loss of T cell tolerance to RBC autoantigens, and to modulate the immune response in AIHA.


Subject(s)
Anemia, Hemolytic, Autoimmune/immunology , Autoantigens/chemistry , Immunodominant Epitopes/chemistry , T-Lymphocytes/immunology , Amino Acid Motifs , Anemia, Hemolytic, Autoimmune/etiology , Anemia, Hemolytic, Autoimmune/genetics , Animals , Anion Exchange Protein 1, Erythrocyte/chemistry , Anion Exchange Protein 1, Erythrocyte/genetics , Anion Exchange Protein 1, Erythrocyte/immunology , Anion Exchange Protein 1, Erythrocyte/metabolism , Autoantigens/genetics , Autoantigens/metabolism , Binding Sites , Binding, Competitive , Histocompatibility Antigens Class II/metabolism , Immunodominant Epitopes/genetics , Immunodominant Epitopes/metabolism , In Vitro Techniques , Lymphocyte Activation , Mice , Mice, Inbred NZB , Peptide Fragments/chemistry , Peptide Fragments/genetics , Peptide Fragments/immunology , Peptide Fragments/metabolism , Protein Binding
3.
Expert Rev Mol Med ; 4(21): 1-16, 2002 Oct 01.
Article in English | MEDLINE | ID: mdl-14585161

ABSTRACT

The role of cholera toxin and heat-labile enterotoxin in the pathogenesis of diarrhoeal disease has been well documented for many years. In addition to these deleterious effects, a wealth of data is accumulating that suggests that these toxins and their subunits might be used to modulate immune responses in a variety of beneficial ways. In this regard, the toxins can boost immune responses to unrelated antigens, leading to the possibility of their use in the generation of improved vaccines to a variety of pathogens. Furthermore, recent evidence suggests that recombinant preparations of the nontoxic B subunits of the toxins have distinct immunomodulatory activities, with potential applications to the treatment of autoimmune and inflammatory diseases. This article reviews our current understanding of the mechanisms of immune modulation by these fascinating proteins.


Subject(s)
Adjuvants, Immunologic/pharmacology , Bacterial Toxins/pharmacology , Cholera Toxin/pharmacology , Enterotoxins/pharmacology , Escherichia coli Proteins , Adjuvants, Immunologic/therapeutic use , Animals , Autoimmune Diseases/drug therapy , Bacterial Toxins/therapeutic use , Cholera Toxin/therapeutic use , Enterotoxins/therapeutic use , Humans , Mice , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...